Plain language summary of a study looking at the effect of empagliflozin treatment in patients with chronic kidney disease
Alistair Roddick, Sibylle J. Hauske(Heidelberg University), Michaela Petrini(University of Oxford), Svenja Seide(Heidelberg University), Anne Whitehouse(University of Oxford)
Cited by 0
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
|Circulation|2020|282
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
|The Lancet|2022|255
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
|Clinical Kidney Journal|2018|239
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
|The Lancet Diabetes & Endocrinology|2024|148